Skip to content

Depression: all studies

Page 716 of 1,034: studies 7,151 to 7,160 of 10,336, newest first. Back to the depression overview

Research

Bioethics, Sociality, and Mental Illness

The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine April 1, 2023 Magnus Englander

The phenomenology of bioethics is approached here in relation to the lived experience as it relates to the everyday lifeworld of persons suffering from mental illness. Taking a road less traveled, the purpose here is to elucidate ethical issues relating to sociality, using findings from qualitative phenomenological psychological research. Qualitative studies of schizophrenia and postpartum...

Improvement in Anxiety Symptoms in Depressed Patients Treated With AXS-05 (DEXTROMETHORPHAN-BUPROPION): Results From the Evolve Open-Label, Long-Term Study

CNS Spectrums April 1, 2023 Amanda Jones, Caroline Streicher, Shawn Alter et al.

AbstractBackgroundInnovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed.AXS-05 (dextromethorphan HBr 45 mg-bupropion HCl 105 mg) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion...

AXS-05 (DEXTROMETHORPHAN-BUPROPION) Improves Depressive Symptoms and Functioning in Patients With One Prior Treatment Failure: Results From the Evolve Long-Term, Open Label Study

CNS Spectrums April 1, 2023 Amanda Jones, Caroline Streicher, Shawn Alter et al.

AbstractBackgroundIn STAR*D, following non-remission with an SSRI, remission rates for second-line treatments were ~ 25%, regardless of the switch strategy employed. Antidepressants with novel mechanisms may improve outcomes in MDD. AXS-05 (dextromethorphan HBr 45 mg- bupropion HCl 105 mg) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity. The dextromethorphan...

Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior

Palliative & Supportive Care April 1, 2023 Fernando Espí Forcén, Laura Marengo, Maya Behn

AbstractThere is a current debate in society as to whether depression can be a terminal illness. Meaning-centered psychotherapy (MCP) and psychedelic medicines have both been shown to treat existential distress in palliative care settings. We are reporting the case of a patient for whom MCP combined with ketamine was an effective treatment for his recurrent and severe depressive disorder with...

Gli psichedelici: quanto è efficace e sicuro il loro possibile impiego in psichiatriae psicoterapia? Lo stato delle evidenze

PNEI REVIEW April 1, 2023 Francesco Dente

Nell'ultimo decennio la ricerca sull'utilizzo terapeutico degli psichedelici ha subito un'impennata, soprattutto per quanto riguarda la loro poten- ziale applicazione nel trattamento dei disturbi psichiatrici. In questi studi è stata indagata la sicurezza e l'efficacia delle varie sostanze psichedeliche, come gli psichedelici classici (psilocibina, ayahuasca e LSD) la ketamina e l'MDMA. Gli...

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Journal of Affective Disorders April 1, 2023 Nadav Liam Modlin, Tammy M Miller, James J Rucker et al. 30 citations

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric...

DOI: 10.1016/j.jad.2023.01.077 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Optimizing psychedelics Treatment outcomes Psilocybin treatment +3

Microbiota-derived psychedelics: Lessons from COVID-19.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University April 1, 2023 Adonis Sfera, Sabine Hazan, Zisis Kozlakidis et al. 7 citations

Emil Kraepelin believed that dementia praecox, the disorder we now call schizophrenia, was caused by the brain being poisoned with toxins generated in other parts of the body, especially the mouth, intestine or genitals. In this regard, Kraepelin hinted at the microbiome and conceptualized microbial molecules as drivers of severe psychiatric illness. However, it was not until the coronavirus...

DOI: 10.17219/acem/159477 (opens in new tab) Full text (opens in new tab) Gut microbes Serotonergic hallucinogens Severe psychiatric illness Gut bacteria +5

Ayahuasca e saúde mental: efeitos do seu uso associado a casos de depressão

Estudos Interdisciplinares em Psicologia March 30, 2023 Lucas Daniel Dos Santos, Wallisten Passos Garcia

O aumento de casos de depressão na população mundial leva ao questionamento sobre a eficácia dos tratamentos farmacológicos e fomenta a busca por tratamentos alternativos. Estudos a respeito da ayahuasca e seus efeitos na depressão vêm sendo realizados. Por meio de uma revisão integrativa, a partir da questão norteadora: “Quais são os efeitos da ayahuasca em indivíduos com depressão?”, neste...

Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology

Nature Communications March 29, 2023 Fangyun Tian, Laura D. Lewis, David W. Zhou et al. 63 citations

The neural mechanisms underpinning ketamine’s dissociative and antidepressant effects remain poorly understood. Here, the authors analyzed ketamine-induced brain dynamics with intracranial recordings in humans and found that ketamine engages different brain areas in distinct frequency-dependent patterns that may relate to its dissociative and antidepressant effects. Ketamine produces...

Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability

Neurology International March 28, 2023 Amber N. Edinoff, Saveen Sall, Colby B. Koontz et al. 5 citations

While driving under the influence of drugs, drivers are more likely to be involved in and cause more accidents than drivers who do not drive under the influence. Ketamine is derived from phencyclidine and acts as a noncompetitive antagonist and allosteric modulator of N-methyl-D-aspartate receptors. Ketamine has been used to treat a variety of psychiatric disorders, with the most notable being...